Summit Therapeutics Inc. filed a Form 8-K on November 16, 2026, disclosing that the U.S. Food and Drug Administration issued a Complete Response Letter on November 15, 2026, regarding the Biologics License Application for ivonescimab in combination with platinum-containing chemotherapy for certain non-small cell lung cancer patients.

Key Highlights

  • CRL Issued: The FDA issued a Complete Response Letter stating the BLA for ivonescimab cannot be approved in its present form.
  • Indication: The BLA covers ivonescimab in combination with platinum-containing chemotherapy for locally advanced or metastatic non-small cell lung cancer patients who received prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
  • FDA's Rationale: According to the filing, the FDA determined that "substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival improvement."
  • PFS Finding: The FDA indicated that "the progression-free survival benefit in the absence of a statistically significant OS benefit does not support a positive benefit-risk profile in support of approval."
  • Exchange and Ticker: Common stock is listed on NASDAQ:SMMT with a par value of $0.01 per share.

FDA Rejects Ivonescimab BLA for NSCLC Over Lack of Survival Data

Summit Therapeutics Inc., headquartered in Miami, Florida, disclosed in an 8-K current report filed November 16, 2026, that the FDA issued a Complete Response Letter on November 15, 2026, for its Biologics License Application for ivonescimab. The BLA sought approval of ivonescimab in combination with platinum-containing chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer who had previously received epidermal growth factor receptor tyrosine kinase inhibitor therapy.

According to the filing, the CRL indicates the BLA "cannot be approved in its present form." The FDA's stated basis is that "substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival improvement." The filing further notes that the FDA communicated the progression-free survival benefit observed in the trial data does not, on its own, support a positive benefit-risk profile sufficient for approval.

The filing states that a press release dated November 15, 2026, was attached as Exhibit 99.1 and incorporated by reference. The 8-K was signed by Manmeet S. Soni, identified in the filing as Chief Operating Officer, Chief Financial Officer and Director, serving as Principal Financial Officer.

What Was Disclosed

Summit Therapeutics disclosed receipt of an FDA Complete Response Letter for its ivonescimab BLA, with the agency citing the absence of a statistically significant overall survival improvement as the basis for its determination that the application cannot be approved in its present form.